AstraZeneca PLC Directorate Change (4087J)
19 Agosto 2019 - 8:00AM
UK Regulatory
TIDMAZN
RNS Number : 4087J
AstraZeneca PLC
19 August 2019
19 August 2019 07:00 BST
AstraZeneca appoints Michel Demaré to its Board of Directors
AstraZeneca today announced that, with effect from 1 September
2019, Michel Demaré is appointed as a Non-Executive Director and a
member of the Audit Committee.
Leif Johansson, Chairman of AstraZeneca, said: "We are delighted
to appoint Michel Demaré as a Director. He has a great deal of
industrial, financial and board-level experience across a range of
sectors including science and technology, that will enable him to
contribute well to the work of our Board and Audit Committee."
Michel Demaré is a Non-Executive Director of Vodafone Group Plc
and a member of the Supervisory Board of Louis Dreyfus Company
Holdings BV. He is Vice-Chairman and Chairman-designate of the IMD
executive business school in Lausanne, and a member of the Advisory
Board of the Department of Banking and Finance at the University of
Zurich.
Mr Demaré was Vice-Chairman of UBS Group AG from 2010 to 2019,
Chairman of Syngenta and the Syngenta Foundation for Sustainable
Agriculture from 2013 to 2017 and Chairman of SwissHoldings from
2013 to 2015.
Mr Demaré joined ABB Ltd in 2005 as Chief Financial Officer
(CFO) and member of the Group Executive Committee. For most of
2008, he acted as the interim Chief Executive Officer of ABB. From
late 2008 to 2011, he combined his role as CFO with that of
President of Global Markets.
He joined ABB from Baxter International Inc., where he was CFO
Europe from 2002 to 2005. Prior to that, he spent 18 years at the
Dow Chemical Company, holding various treasury and risk management
positions in Belgium, France, the US and Switzerland. Between 1997
and 2002, Mr Demaré was CFO of the Global Polyolefins and
Elastomers division. He began his career as a banking officer in
the multinational banking division of Continental Illinois' Belgian
subsidiary.
Mr Demaré graduated with an MBA from the Katholieke Universiteit
Leuven, Belgium, and holds a degree in applied economics from the
Université Catholique de Louvain, Belgium.
Except as set out above, no disclosure obligations arise under
paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's
Listing Rules in respect of this appointment.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, CVRM and Respiratory. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals (cardiovascular, metabolism) +44 203 749 5711
Nick Stone BioPharmaceuticals (respiratory, renal) +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Kretzmann Corporate access, retail investors +44 203 749 5824
US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOASFUSWAFUSEFA
(END) Dow Jones Newswires
August 19, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024